Broker sees possible higher bid for Medivation
French drug group offers US$9.3bn for prostate cancer specialist
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 49 of 55
PREVIEW: Can AstraZeneca follow Glaxo with better-than-expected quarterlies?
AstraZeneca releases first quarter results on Friday, the schedule also includes Shire, BA owner International Consolidated Airlines, and Royal Bank of Scotland Group.
UK shares finish as they started as traders eye Fed meet
UK shares ended the day in similar fashion as they begun, with big caps outshining smaller stocks.
Week Ahead: Investors look out for Apple, Twitter, Facebook and BP results
After Silicon Valley giants Alphabet and Microsoft disappointed this week, next Tuesday brings Apple Inc’s second-quarter earnings.
London shares recover after oil-stained session
The FTSE 100 Index closed 9.77 points higher at 6,353
AstraZeneca tipped to bid for US cancer specialist
AstraZeneca has reportedly held talks with San Francisco-based Medivation
Small caps recover from oil woe as drug M&A talk swirls
Small caps pare losses but Footsie drops nearly 20 points
Stocks dip after oil talks fail, but drug M&A chat injects interest
Indices drop after Iran's absence at talks scuppers hopes of price freeze
Archive
Unilever catches Credit Suisse’s eye
Credit Suisse is bullish on consumer goods giant Unilever PLC ahead of first quarter results on April 14 and has ramped up the target price.
AstraZeneca PLC's US$100mln boost as Eli Lilly collaboration moves to next stage
Lilly has made what’s known as a milestone payment following progress in developing a treatment called AZD3293 for early stage Alzheimer's disease.
Investments and investor services
Stocks advance, led by Botswana Diamonds PLC and Cyan Holdings PLC
Throughout the day Botswana Diamonds and Cyan Holdings competed to be the biggest riser on the day.
Trending: Pfizer tie up with Allergan catches a cold
Not for the first time has the ambitious and acquisitive pharmaceutical behemoth Pfizer has been upset at the merger altar, but with its Allergan deal under threat, the company may well step back and assess shareholder value
Archive
Drug companies inject interest into lacklustre London market
PureTech Health told investors it had expanded its focus on microbiome-based interventions
AstraZeneca's heart drug Brilinta fails in trial
Drug group said blood-thinning treatment missed targets for reducing repeat stroke and heart attacks
Synairgen makes progress with lung drug
Lung drug developer says tests showed success in treating idiopathic pulmonary fibrosis
Archive
AstraZeneca PLC lacks catalysts for 2016 - Jefferies
Broker Jefferies has cut its rating on drugs giant AstraZeneca PLC to 'hold' from 'buy' saying there's a lack of catalysts in 2016 to re-rate shares.
RedX tipped for success as Cantor assesses pharmas
Cantor now rates RedX as a ‘buy’, and with a 105p target the broker sees some 150% upside to the current price of 41.5p.
Archive
Jefferies downgrades targets on Glaxo and Astra
US heavyweight Jefferies looks at global pharma today and downgraded Glaxo and AstraZeneca...